GSK plc (GSK)
Pre-market:
| Previous close | 40.86 |
| Open | 41.06 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1000 |
| Day's range | 40.81 - 41.11 |
| 52-week range | 33.33 - 43.84 |
| Volume | |
| Avg. volume | 3,491,038 |
| Market cap | 83.58B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 13.68 |
| EPS (TTM) | 2.99 |
| Earnings date | N/A |
| Forward dividend & yield | 1.47 (3.59%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | 45.39 |
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
- Reuters
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
ReutersGlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
